Vessel normalization following treatment with SFN or other RTK inhibitors has already been described for various cancers (Wilhelm et al., 2006; Sorensen et al., 2012; Batchelor et al., 2007, 2013; Navis et al., 2013). Here, SFN is linked to cancer.